by: Parent Project Muscular Dystrophy
PPMD recently held a community webinar with Capricor Therapeutics, during which the company shared their most recent results from the Phase 3 HOPE-3 trial evaluating deramiocel (CAP-1002), Capricor’s investigational cell therapy for the treatment of Duchenne muscular dystrophy. The presentation included a review of the data, a discussion of planned next steps for FDA engagement and regulatory strategy, and a dedicated Q&A period.
